Patterns of injection drug use cessation during an expansion of syringe exchange services in a Canadian setting

Drug and Alcohol Dependence

Volumn 132, Issue 3, 2013, Pages 535-540

  Werb, Dan ^a   Kerr, Thomas ^a   Buxton, Jane ^b   Shoveller, Jeannie ^c   Richardson, Chris ^c   Montaner, Julio ^a   Wood, Evan ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cessation; Injection drug use; Needle exchange programme; Vancouver

Indexed keywords

ADULT; ARTICLE; CANADA; CONTROLLED STUDY; DRUG ABUSE PATTERN; FEMALE; HEALTH BEHAVIOR; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INJECTION DRUG USE CESSATION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NEEDLE AND SYRINGE PROGRAM; PRIORITY JOURNAL; RISK REDUCTION;

CESSATION; INJECTION DRUG USE; NEEDLE EXCHANGE PROGRAMME; VANCOUVER;

ADULT; CANADA; COHORT STUDIES; FEMALE; HUMANS; MALE; NEEDLE SHARING; NEEDLE-EXCHANGE PROGRAMS; PROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84883551230     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.03.024     Document Type: Article

References (45)

1. Beyrer C., Malinowska-Sempruch K., Kamarulzaman A., Kazatchkine M., Sidibe M., Strathdee S.A. Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet 2010, 376:551-563.
2. Broadhead R.S., Heckathorn D.D., Weakliem D.L., Anthony D.L., Madray H., Mills R.J., Hughes J. Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. Public Health Rep. 1998, 113(Suppl. 1):42.
3. Bruneau J., Brogly S.B., Tyndall M.W., Lamothe F., Franco E.L. Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization. Addiction 2004, 99:727.
4. Bruneau J., Lamothe F., Franco E., Lachance N., Desy M., Soto J., Vincelette J. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am. J. Epidemiol. 1997, 146:994.
5. Buxton, J., Mehrabadi, A., Preston, E., Tu, A., 2007. Vancouver Site Report for the Canadian Community Epidemiology Network on Drug Use. City of Vancouver.
6. Cao W., Treloar C. Comparison of needle and syringe programme attendees and non-attendees from a high drug-using area in Sydney, New South Wales. Drug Alcohol Rev. 2006, 25:439-444.
7. Cochrane Collaborative Review Group on HIV Infection and AIDS Structural Interventions to Increase Needle/Syringe Access for Preventing HIV and Hepatitis C in Injection Drug Users 2010, University of California, San Francisco.
8. Cohen D.A., Wu S.Y., Farley T.A. Comparing the cost-effectiveness of HIV prevention interventions. J. Acquir. Immune Defic. Syndr. 2004, 37:1404.
9. Cooper H.L.F., Des Jarlais D.C., Ross Z., Tempalski B., Bossak B., Friedman S.R. Spatial access to syringe exchange programs and pharmacies selling over-the-counter syringes as predictors of drug injectors' use of sterile syringes. Am. J. Public Health 2011, 101:1118.
10. Degenhardt L., Mathers B., Vickerman P., Rhodes T., Latkin C., Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010, 376:16.
11. Des Jarlais D.C. Structural interventions to reduce HIV transmission among injecting drug users. AIDS 2000, 14:S41.
12. Des Jarlais D.C., Arasteh K., McKnight C., Ringer M., Friedman S.R. Syringe exchange, injecting and intranasal drug use. Addiction 2010, 105:155-158.
13. Diggle P.J., Heagerty P.J., Liang K.-Y., Zeger S.L. Time-dependent Covariates. Analysis of Longitudinal Data 2002, 245-281. Oxford University Press, Oxford.
14. Donoghoe M., Verster A.D., Mathers B. WHO, UNODC, UNAIDS Technical Guide for Countries to Set Targets for Universal Access to HIV Prevention, Treatment and Care for Injecting Drug Users 2009, WHO/UNODC/UNAIDS, Geneva.
15. Drach L., Guernsey J., Maher J.E., Rumptz M., Stark M., Pranian K., Casciato C. Should we move from syringe exchange to distribution?. Am. J. Public Health 2011, 101:389.
16. Genberg B.L., Gange S.J., Go V.F., Celentano D.D., Kirk G.D., Mehta S.H. Trajectories of injection drug use over 20 years (1988-2008) in Baltimore, Maryland. Am. J. Epidemiol. 2011, 173:829-836.
17. Grund J.P., Blanken P., Adriaans N.F., Kaplan C.D., Barendregt C., Meeuwsen M. Reaching the unreached: targeting hidden IDU populations with clean needles via known user groups. J. Psychoactive Drugs 1992, 24:41.
18. Haber P.S., Demirkol A., Lange K., Murnion B., Womack H., Parfitt T. The future of harm reduction programmes in Russia. Lancet 2009, 374:1284-1293.
19. Heimer R., Eicher A., Eno R., Greaves S., Kamina A., Singh M., Soni R., Lopes M., Massaro S. Needle exchange programs as a conduit to drug treatment: the New Haven experience. Int. Conf. AIDS 1996, 11:155. (abstract no. We.C.3561).
20. Horton R., Das P. Rescuing people with HIV who use drugs. Lancet 2010, 376:207-208.
21. Kasperowicz P. DC Delegate: Congress has 'Killed' With Needle Exchange Prohibition. The Hill 2011, Capitol Hill Publishing Corp., Washington, DC.
22. Kerr T., Small W., Buchner C., Zhang R., Li K., Montaner J., Wood E. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am. J. Public Health 2010, 100:1449.
23. Keyes K.M., Utz R.L., Robinson W., Li G. What is a cohort effect? Comparison of three statistical methods for modeling cohort effects in obesity prevalence in the United States, 1971-2006. Soc. Sci. Med. 2010, 70:1100-1108.
24. Latkin C.A. Outreach in natural settings: the use of peer leaders for HIV prevention among injecting drug users' networks. Public Health Rep. 1998, 113(Suppl. 1):151.
25. Leonard L., DeRubeis E., Pelude L., Medd E., Birkett N., Seto J. I inject less as I have easier access to pipes: injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed. Int. J. Drug Policy 2008, 19:255-264.
26. Liang K.Y., Zeger S.L. Longitudinal data using generalized linear models. Biometrika 1986, 73:13.
27. Mathers B.M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R.P., Myers B., Ambekar A., Strathdee S.A. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010, 375:15.
28. Matichon Online Matichon Online 2011, Matichon Public Co., Bangkok.
29. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009, CD002209.
30. Nelson K.E., Galai N., Safaeian M., Strathdee S.A., Celentano D.D., Vlahov D. Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am. J. Epidemiol. 2002, 156:641.
31. PEPFAR Comprehensive HIV Prevention for People Who Inject Drugs, Revised Guidance 2010, President's Emergency Plan for AIDS Relief, Washington, DC.
32. Public Health Agency of Canada I-Track: Enhanced Surveillance of Risk Behaviours Among People who Inject Drugs. Phase I Report, August 2006 2006, 1. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, Ottawa.
33. Remis R.S., Strathdee S.A., Millson M., Leclerc L., Degani N., Palmer R.W.H., Taylor C., Bruneau J., Hogg R.S., Routledge R. Consortium to Characterize Injection Drug Users in Montreal, Toronto and Vancouver, Canada 1998, Bureau of HIV/AIDS, STD and TB, Health Canada, Ottawa.
34. Shah N.G., Galai N., Celentano D.D., Vlahov D., Strathdee S.A. Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000. Drug Alcohol Depend. 2006, 83:147-156.
35. Strathdee S.A., Patrick D.M., Currie S.L., Cornelisse P.G., Rekart M.L., Montaner J.S., Schechter M.T., O'Shaughnessy M.V. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997, 11:F59.
36. Strathdee S.A., Vlahov D. The effectiveness of needle exchange programs: a review of the science and policy. AIDScience 2001, 1:1-31.
37. UNAIDS Joint UNAIDS Statement on HIV Prevention and Care Strategies for Drug Users 2005, Joint United Nations Programme on HIV/AIDS, Geneva.
38. US Congress, 2011. A bill making appropriations for the Department of State, foreign operations, and related programs for the fiscal year ending September 30, 2012, and for other purposes, p. 112.
39. Vancouver Coastal Health, 2011. (accessed 01.09.11). http://www.vch.ca/.
40. Vlahov D., Des Jarlais D.C., Goosby E., Hollinger P.C., Lurie P.G., Shriver M.D., Strathdee S.A. Needle exchange programs for the prevention of human immunodeficiency virus infection: epidemiology and policy. Am. J. Epidemiol. 2001, 154:70.
41. Vlahov D., Junge B., Brookmeyer R., Cohn S., Riley E., Armenian H., Beilenson P. Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program. J. Acquir. Immune Defic. Syndr. 1997, 16:400.
42. von Elm E., Altman D.G., Egger M., Pocock S.J., Getzsche P.C., Vandenbroucke J.P. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007, 4:e296.
43. Voth E.A. Harm reduction drug policy. Lancet Infect. Dis. 2008, 8:528. author reply 528.
44. Wood E., Lloyd-Smith E., Li K., Strathdee S.A., Small W., Tyndall M.W., Montaner J.S., Kerr T. Frequent needle exchange use and HIV incidence in Vancouver, Canada. Am. J. Med. 2007, 120:172-179.
45. Zeger S.L., Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42:121.